LucyRx and Personify Health Partner to Offer Integrated GLP-1 and Weight Management Solution for Employers
What You Should Know: – LucyRx, an independent, next-generation pharmacy benefits manager (PBM), and Personify Health®, the company making healthier easier announced a strategic partnership to offer employers a more personalized, clinically grounded approach to GLP-1 medication management and weight care. – The strategic collaboration will deliver an integrated solution that combines pharmacy benefit strategy […]
Deep Apple signs big Novo deal for cardiometabolic small molecules
Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an unspecified up-front payment, research costs and milestones. The two plan to develop and commercialize oral small molecules for non-incretin G-protein coupled receptor targets for treating cardiometabolic diseases, including […]
McDonald’s downgraded on GLP-1 drug worries: Wall Street’s top analyst calls
Post Content
Lawmakers urge Trump administration to clamp down on illicit GLP-1 sales
A bipartisan group of congressional lawmakers is calling on the Trump administration to address the continued sale of illicit, compounded GLP-1 products, warning that consumers may be accessing these drugs without knowing the product could be fraudulent. North Carolina Reps. Brad Knott (R) and Deborah Ross (D) wrote to Food and Drug Administration (FDA) Commissioner […]
Fatty Liver a Major Health Risk: Experts
Nonalcoholic fatty liver disease refers to a range of conditions in which fatty deposits occur in the liver. (Representational Image)Nonalcoholic fatty liver disease refers to a range of conditions in which fatty deposits occur in the liver. (Representational Image) �Hyderabad: Fatty liver disease, once considered a minor issue, has now emerged as a serious public […]
Study: Real-world results of GLP-1 drugs don’t match trials
Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren’t as impressive as those promised by the drugs’ clinical trials, a new study says.
Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?
Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both have witnessed rapid demand despite being on the market for less than three years. Mounjaro and Zepbound include the same compound tirzepatide, a dual GIP and GLP-1 receptor agonist. Mounjaro and Zepbound generated combined sales […]
Reality check: Unpacking the $150B GLP-1 market forecasts
Market expectations for GLP-1 agonists have been high for some time. But in the past year, sales forecasts have gone stratospheric. Last month, Morgan Stanley Research upped its 2035 peak estimate for the obesity drug …
Cleveland Clinic Research Finds Injectable Medications for Obesity Produce Smaller Weight Loss in A Real-World Setting, Compared to Randomized Clinical Trials – Cleveland Clinic Newsroom
Cleveland Clinic Research Finds Injectable Medications for Obesity Produce Smaller Weight Loss in A Real-World Setting, Compared to Randomized Clinical Trials Cleveland Clinic Newsroom Real-World Use of GLP-1s Yields Less Weight Loss Than Clinical Trials AJMC Real-World Results For GLP-1 Drugs Underwhelm, Study Says U.S. News & World Report Weight loss drugs don’t work as well for people […]
Use of GLP-1 RAs is associated with a 2-fold higher risk of Macular Degeneration
Comments